Edition:
United Kingdom

Odonate Therapeutics Inc (ODT.OQ)

ODT.OQ on NASDAQ Stock Exchange Global Select Market

34.30USD
16 Jul 2019
Change (% chg)

$-0.87 (-2.47%)
Prev Close
$35.17
Open
$35.14
Day's High
$35.41
Day's Low
$33.96
Volume
56,338
Avg. Vol
33,071
52-wk High
$37.99
52-wk Low
$11.68

Latest Key Developments (Source: Significant Developments)

Odonate Therapeutics Says Offering Of Common Shares Priced At $26/Share
Wednesday, 26 Jun 2019 

June 26 (Reuters) - Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.75 MILLION COMMON SHARES PRICED AT $26.00PER SHARE.  Full Article

Odonate Therapeutics Announces Public Offering Of Shares Of Common Stock
Tuesday, 25 Jun 2019 

Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF SHARES OF COMMON STOCK.ODONATE THERAPEUTICS - COMMENCED PUBLIC OFFERING OF ABOUT $100 MILLION OF SHARES OF ITS COMMON STOCK.ODONATE THERAPEUTICS - TO USE PROCEEDS FROM PROPOSED UNDERWRITTEN PUBLIC OFFERING FOR DEVELOPMENT AND REGULATORY ACTIVITIES RELATING TO TESETAXEL.  Full Article

Odonate Therapeutics Q4 Loss Per Share $1.17
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2018.Q4 LOSS PER SHARE $1.17.AS OF DECEMBER 31, 2018, ODONATE HAD $139.1 MILLION IN CASH, COMPARED TO $198.1 MILLION AS OF DECEMBER 31, 2017..EXPECT TO COMPLETE ENROLLMENT IN PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER, IN H2 OF 2019.EXPECT TO REPORT TOP-LINE RESULTS FROM PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER IN 2020.  Full Article

Odonate TherapeuticsFiles For Stock Offering Of Upto $150 Mln
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Odonate Therapeutics Inc ::FILES FOR STOCK OFFERING OF UPTO $150 MILLION .  Full Article

Odonate Therapeutics Q3 Loss Per Share $0.98
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018.Q3 LOSS PER SHARE $0.98.  Full Article

Odonate Therapeutics Qtrly Loss Per Share $0.79
Monday, 30 Jul 2018 

July 30 (Reuters) - Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018.ODONATE THERAPEUTICS INC - AS OF JUNE 30, 2018, ODONATE HAD $177.4 MILLION IN CASH.ODONATE THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.79.  Full Article

Odonate Holdings Llc Reports A 11.5 Pct Stake In Odonate Therapeutics As Of Dec 6
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Odonate Holdings Llc ::Reports A 11.5 Pct Stake In Odonate Therapeutics Inc AS OF DEC 6 - SEC FILING.  Full Article

Boxer Capital LLC Reports 10.0 Pct Stake In Odonate Therapeutics As Of Dec 6
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Odonate Therapeutics Inc ::BOXER CAPITAL LLC REPORTS 10.0 PERCENT STAKE IN ODONATE THERAPEUTICS INC AS OF DECEMBER 6 - SEC FILING.BOXER CAPITAL LLC SAYS ACQUIRED POSITIONS IN ODONATE THERAPEUTICS INC'S COMMON STOCK FOR INVESTMENT PURPOSES.  Full Article

Odonate Therapeutics Shares Debut 4.2 Pct Below IPO Price
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - :ODONATE THERAPEUTICS SHARES OPEN AT $23.00 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $24.00/SHARE.  Full Article

Odonate Therapeutics Announces Pricing Of Initial Public Offering
Thursday, 7 Dec 2017 

Odonate Therapeutics Llc ::ODONATE THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.ODONATE THERAPEUTICS LLC- ‍ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $24.00​.  Full Article